Get the Stockscreener App
1.29
6.61%
0.08
Marker Therapeutics Inc stock is traded at $1.29, with a volume of 101.56K.
It is up +6.61% in the last 24 hours and down -18.35% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.21
Open:
$1.2
24h Volume:
101.56K
Relative Volume:
0.09
Market Cap:
$14.60M
Revenue:
-
Net Income/Loss:
$-9.70M
P/E Ratio:
-1.1727
EPS:
-1.1
Net Cash Flow:
$-8.57M
1W Performance:
+2.38%
1M Performance:
-18.35%
6M Performance:
-17.83%
1Y Performance:
-64.66%
1-Day Range:
$1.20
$1.31
1-Week Range:
$1.11
$1.31
52-Week Range:
$0.95
$5.95
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.29 | 13.69M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Exit strategy if you’re trapped in Marker Therapeutics Inc.Trade Performance Summary & Growth Focused Stock Pick Reports - Newser
Published on: 2025-08-21 02:07:42 - newsyoung.net
Is it time to cut losses on Marker Therapeutics Inc.Quarterly Trade Summary & Weekly Watchlist for Consistent Profits - Newser
Can you recover from losses in Marker Therapeutics Inc.Earnings Overview Summary & Community Verified Swing Trade Signals - Newser
Can machine learning forecast Marker Therapeutics Inc. recovery2025 Volatility Report & Short-Term Trading Alerts - Newser
Is Marker Therapeutics Inc. forming a bottoming baseWeekly Trade Analysis & Safe Swing Trade Setups - Newser
Can trapped investors hope for a rebound in Marker Therapeutics Inc.Trade Ideas & Weekly Top Gainers Trade List - Newser
Momentum divergence signals in Marker Therapeutics Inc. chartJuly 2025 News Drivers & High Conviction Buy Zone Picks - Newser
Watch for Bullish Crossover in Marker Therapeutics Inc.July 2025 Weekly Recap & Community Supported Trade Ideas - Newser
Short interest data insights for Marker Therapeutics Inc.2025 Macro Impact & Low Risk Entry Point Tips - Newser
Marker Therapeutics Inc. Rebound Backed by Sentiment ShiftTrade Ideas & Verified Momentum Stock Watchlist - classian.co.kr
Applying chart zones and confluence areas to Marker Therapeutics Inc.July 2025 Summary & Daily Stock Trend Reports - Newser
What makes Marker Therapeutics Inc. stock attractive to long term investorsJuly 2025 Update & Short-Term Swing Trade Alerts - Newser
Marker Therapeutics Posts Q2 2025 Earnings Loss Amid Weak Market Reaction - AInvest
Is Marker Therapeutics Inc. meeting your algorithmic filter criteriaTrade Risk Assessment & Expert Approved Momentum Trade Ideas - Newser
Will Marker Therapeutics Inc. continue its uptrendJuly 2025 News Drivers & Stock Market Timing Techniques - Newser
Using Bollinger Bands to evaluate Marker Therapeutics Inc.2025 Market Outlook & Low Risk Profit Maximizing Plans - Newser
Using economic indicators to assess Marker Therapeutics Inc. potentialWeekly Trade Recap & Safe Capital Preservation Plans - Newser
Marker Therapeutics Posts Q2 2025 Earnings Loss Amid High Costs and Weak Market Reaction - AInvest
Is Marker Therapeutics Inc. a Top Dividend Stock to Watch in 2025Quarterly Investment Review & Fast Moving Trade Plans - Newser
Is Marker Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideWeekly Gains Report & AI Driven Price Forecasts - Newser
Will Marker Therapeutics Inc. see short term momentumJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - Newser
Price action breakdown for Marker Therapeutics Inc.Insider Selling & Weekly Return Optimization Plans - Newser
What MACD signals say about Marker Therapeutics Inc.Earnings Growth Summary & Safe Capital Growth Plans - Newser
Wall Street Zen Upgrades Marker Therapeutics (NASDAQ:MRKR) to “Sell” - Defense World
Can Marker Therapeutics Inc. hit a new high this monthInsider Buying & Safe Capital Investment Plans - Newser
Using Ichimoku Cloud for Marker Therapeutics Inc. technicalsJuly 2025 Selloffs & Free High Return Stock Watch Alerts - Newser
Published on: 2025-08-15 15:19:17 - metal.it
Marker Therapeutics Reports Increased R&D Expenses Amid Revenue Decline - TipRanks
Marker Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Marker Therapeutics, Inc. SEC 10-Q Report - TradingView
Promising Developments and Market Potential Drive Buy Rating for Marker Therapeutics - TipRanks
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marker Therapeutics Inc Stock (MRKR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):